Literature DB >> 2831282

Attenuation of bovine parainfluenza virus type 3 in nonhuman primates and its ability to confer immunity to human parainfluenza virus type 3 challenge.

K L van Wyke Coelingh1, C C Winter, E L Tierney, W T London, B R Murphy.   

Abstract

Bovine parainfluenza virus type 3 (PIV-3) was evaluated as a candidate live-virus vaccine to protect against infection with human PIV-3. The level of replication of bovine and human PIV-3 and the efficacy of immunization with bovine PIV-3 in protecting against subsequent challenge with human PIV-3 was evaluated in nonhuman primates. The duration and magnitude of replication of human and bovine PIV-3 in the upper and lower respiratory tracts of New World monkeys was similar, and animals infected with bovine PIV-3 developed resistance to challenge with human PIV-3. The replication of two bovine strains of PIV-3 was restricted 100- to 1000-fold in Old World primates but was sufficient to induce high levels of neutralizing antibody to human PIV-3. The combined properties of restricted replication and induction of a protective immune response to human PIV-3 in nonhuman primates make bovine PIV-3 a promising candidate for a live-virus vaccine to protect humans against disease caused by PIV-3.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2831282     DOI: 10.1093/infdis/157.4.655

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  35 in total

1.  Expression of the surface glycoproteins of human parainfluenza virus type 3 by bovine parainfluenza virus type 3, a novel attenuated virus vaccine vector.

Authors:  A A Haller; T Miller; M Mitiku; K Coelingh
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

2.  A recombinant human parainfluenza virus type 3 (PIV3) in which the nucleocapsid N protein has been replaced by that of bovine PIV3 is attenuated in primates.

Authors:  J E Bailly; J M McAuliffe; A P Durbin; W R Elkins; P L Collins; B R Murphy
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

3.  Evaluation of bovine, cold-adapted human, and wild-type human parainfluenza type 3 viruses in adult volunteers and in chimpanzees.

Authors:  M L Clements; R B Belshe; J King; F Newman; T U Westblom; E L Tierney; W T London; B R Murphy
Journal:  J Clin Microbiol       Date:  1991-06       Impact factor: 5.948

4.  Enhanced Neutralizing Antibody Response Induced by Respiratory Syncytial Virus Prefusion F Protein Expressed by a Vaccine Candidate.

Authors:  Bo Liang; Sonja Surman; Emerito Amaro-Carambot; Barbora Kabatova; Natalie Mackow; Matthias Lingemann; Lijuan Yang; Jason S McLellan; Barney S Graham; Peter D Kwong; Anne Schaap-Nutt; Peter L Collins; Shirin Munir
Journal:  J Virol       Date:  2015-07-08       Impact factor: 5.103

5.  Antigenic and functional organization of human parainfluenza virus type 3 fusion glycoprotein.

Authors:  K van Wyke Coelingh; E L Tierney
Journal:  J Virol       Date:  1989-01       Impact factor: 5.103

6.  Sequence determination and molecular analysis of two strains of bovine parainfluenza virus type 3 that are attenuated for primates.

Authors:  J E Bailly; J M McAuliffe; M H Skiadopoulos; P L Collins; B R Murphy
Journal:  Virus Genes       Date:  2000       Impact factor: 2.332

7.  Effects of human metapneumovirus and respiratory syncytial virus antigen insertion in two 3' proximal genome positions of bovine/human parainfluenza virus type 3 on virus replication and immunogenicity.

Authors:  Roderick S Tang; Jeanne H Schickli; Mia MacPhail; Fiona Fernandes; Leenas Bicha; Joshua Spaete; Ron A M Fouchier; Albert D M E Osterhaus; Richard Spaete; Aurelia A Haller
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

8.  Complete genome sequence and pathogenicity of two swine parainfluenzavirus 3 isolates from pigs in the United States.

Authors:  Dan Qiao; Bruce H Janke; Subbiah Elankumaran
Journal:  J Virol       Date:  2009-11-11       Impact factor: 5.103

9.  Human PIV-2 recombinant Sendai virus (rSeV) elicits durable immunity and combines with two additional rSeVs to protect against hPIV-1, hPIV-2, hPIV-3, and RSV.

Authors:  Bart Jones; Xiaoyan Zhan; Vasiliy Mishin; Karen S Slobod; Sherri Surman; Charles J Russell; Allen Portner; Julia L Hurwitz
Journal:  Vaccine       Date:  2009-02-04       Impact factor: 3.641

10.  The two major human metapneumovirus genetic lineages are highly related antigenically, and the fusion (F) protein is a major contributor to this antigenic relatedness.

Authors:  Mario H Skiadopoulos; Stéphane Biacchesi; Ursula J Buchholz; Jeffrey M Riggs; Sonja R Surman; Emerito Amaro-Carambot; Josephine M McAuliffe; William R Elkins; Marisa St Claire; Peter L Collins; Brian R Murphy
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.